DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results May 15, 2019 • 5:30 AM EDT
DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering May 8, 2019 • 8:12 AM EDT
DelMar Presents Data Supporting VAL-083 as Potential Treatment for Pediatric Brain Tumors at SNO Pediatric Neuro-Oncology Conference May 6, 2019 • 5:30 AM EDT
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board April 4, 2019 • 5:30 AM EDT
DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083 April 3, 2019 • 5:30 AM EDT
DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM February 20, 2019 • 5:30 AM EST
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results February 12, 2019 • 5:30 AM EST